AtriCure (ATRC) Misses Q1 EPS by 1c

AtriCure (NASDAQ: ATRC) reported Q1 EPS of ($0.33), $0.01 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $74.6 million versus the consensus estimate of $71.17 million.

GUIDANCE:

AtriCure sees FY2022 revenue of $318-330 million, versus the consensus of $321.7 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c